NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CTSO Stock Alerts $0.95 +0.02 (+2.15%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.87▼$0.9650-Day Range$0.86▼$1.0452-Week Range$0.84▼$4.29Volume116,409 shsAverage Volume102,768 shsMarket Capitalization$51.58 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cytosorbents alerts: Email Address Cytosorbents MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside163.2% Upside$2.50 Price TargetShort InterestHealthy3.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.51 out of 5 starsMedical Sector733rd out of 938 stocksSurgical & Medical Instruments Industry77th out of 94 stocks 3.3 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, Cytosorbents has a forecasted upside of 163.2% from its current price of $0.95.Amount of Analyst CoverageCytosorbents has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.08% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Cytosorbents has recently decreased by 2.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTSO. Previous Next 2.5 News and Social Media Coverage News SentimentCytosorbents has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cytosorbents this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.46) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Cytosorbents Stock (NASDAQ:CTSO)Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More CTSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTSO Stock News HeadlinesMarch 20, 2024 | americanbankingnews.comB. Riley Weighs in on Cytosorbents Co.'s Q1 2024 Earnings (NASDAQ:CTSO)March 20, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Cytosorbents Co.'s FY2025 Earnings (NASDAQ:CTSO)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 19, 2024 | americanbankingnews.comHC Wainwright Reiterates Neutral Rating for Cytosorbents (NASDAQ:CTSO)March 16, 2024 | finance.yahoo.comCytosorbents Full Year 2023 Earnings: Misses ExpectationsMarch 16, 2024 | finance.yahoo.comCTSO Apr 2024 2.500 callMarch 15, 2024 | finance.yahoo.comQ4 2023 Cytosorbents Corp Earnings CallMarch 15, 2024 | finance.yahoo.comCytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 14, 2024 | benzinga.comRecap: CytoSorbents Q4 EarningsMarch 14, 2024 | globenewswire.comCytoSorbents Reports Fourth Quarter and Full Year 2023 ResultsMarch 13, 2024 | markets.businessinsider.comCytosorbents earnings preview: what to expectMarch 6, 2024 | globenewswire.comCytoSorbents to Report Fiscal 2023 Operating and Financial ResultsMarch 4, 2024 | finance.yahoo.comCTSO Mar 2024 2.500 callFebruary 27, 2024 | money.usnews.comCytosorbents CorpFebruary 23, 2024 | finance.yahoo.comCytosorbents (NASDAQ:CTSO) investors are sitting on a loss of 90% if they invested three years agoFebruary 22, 2024 | benzinga.comCytoSorbents Stock (NASDAQ:CTSO) Insider TradesFebruary 22, 2024 | benzinga.comCytoSorbents Stock (NASDAQ:CTSO) Dividends: History, Yield and DatesFebruary 8, 2024 | finance.yahoo.comCytoSorbents to Present at the TD Cowen 44th Annual Health Care ConferenceJanuary 17, 2024 | finance.yahoo.comCTSO: CytoSorbents reports update on data results from important U.S. and Canadian STAR-T pivotal trial.January 17, 2024 | finance.yahoo.comGroundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant PatientsJanuary 6, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSODecember 30, 2023 | msn.comHC Wainwright & Co. Downgrades Cytosorbents (CTSO)December 30, 2023 | markets.businessinsider.comCytoSorbents Holds Steady with Neutral Rating Amid Clinical and Financial ReassessmentsDecember 29, 2023 | realmoney.thestreet.comCytoSorbents just downgraded at H.C. Wainwright, here's whyDecember 29, 2023 | markets.businessinsider.comWhat To Know About HC Wainwright & Co.'s Downgrade of CytoSorbentsDecember 28, 2023 | markets.businessinsider.comCytoSorbents: DrugSorb-ATR Study Fails To Meet Primary Effectiveness EndpointSee More Headlines Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/29/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees198Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$4.00 Low Stock Price Target$1.00 Potential Upside/Downside+163.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,510,000.00 Net Margins-78.43% Pretax Margin-80.67% Return on Equity-120.24% Return on Assets-54.11% Debt Debt-to-Equity Ratio0.11 Current Ratio1.77 Quick Ratio1.51 Sales & Book Value Annual Sales$36.35 million Price / Sales1.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book1.83Miscellaneous Outstanding Shares54,290,000Free Float49,896,000Market Cap$51.58 million OptionableOptionable Beta0.58 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Phillip P. Chan M.D. (Age 54)Ph.D., CEO & Director Comp: $541.93kMr. Vincent J. Capponi M.S. (Age 66)President & COO Comp: $452.62kMs. Kathleen P. Bloch CPA (Age 69)M.B.A., Chief Financial Officer Comp: $395.43kDr. Efthymios N. Deliargyris FACC (Age 56)FESC, FSCAI, M.D., Chief Medical Officer Comp: $463.15kMs. Terri Anne Powers M.B.A.Vice President of Investor Relations & Corporate CommunicationsDr. Christian Steiner M.D.Executive Vice President of Sales & MarketingMr. Christopher Cramer M.B.A.M.S., Senior Vice President of Business DevelopmentDr. Irina B. Kulinets Ph.D. (Age 69)Senior Vice President of Global Regulatory Affairs Jodi HooverExecutiveDr. Robert H. Bartlett M.D. (Age 85)Co-Chairman of Cardiac Surgery Advisory Board & Consultant Comp: $54kMore ExecutivesKey CompetitorsApyx MedicalNASDAQ:APYXLucid DiagnosticsNASDAQ:LUCDIceCure MedicalNASDAQ:ICCMInspireMDNYSE:NSPRModular MedicalNASDAQ:MODDView All CompetitorsInsiders & InstitutionsGranahan Investment Management LLCBought 2,065,750 shares on 2/15/2024Ownership: 8.142%Citadel Advisors LLCSold 2,100 shares on 2/15/2024Ownership: 0.000%Avenir CorpBought 334,005 shares on 2/14/2024Ownership: 6.866%Neuberger Berman Group LLCBought 299,103 shares on 2/14/2024Ownership: 4.054%Regal Investment Advisors LLCBought 23,013 shares on 2/14/2024Ownership: 0.103%View All Insider TransactionsView All Institutional Transactions CTSO Stock Analysis - Frequently Asked Questions Should I buy or sell Cytosorbents stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTSO shares. View CTSO analyst ratings or view top-rated stocks. What is Cytosorbents' stock price target for 2024? 2 analysts have issued 1 year price targets for Cytosorbents' shares. Their CTSO share price targets range from $1.00 to $4.00. On average, they anticipate the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 163.2% from the stock's current price. View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts. How have CTSO shares performed in 2024? Cytosorbents' stock was trading at $1.11 on January 1st, 2024. Since then, CTSO shares have decreased by 14.4% and is now trading at $0.95. View the best growth stocks for 2024 here. When is Cytosorbents' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our CTSO earnings forecast. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) announced its earnings results on Thursday, November, 4th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company earned $9.76 million during the quarter, compared to analyst estimates of $9.96 million. Cytosorbents had a negative trailing twelve-month return on equity of 120.24% and a negative net margin of 78.43%. During the same quarter last year, the business earned ($0.02) EPS. What is Phillip Chan's approval rating as Cytosorbents' CEO? 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Granahan Investment Management LLC (8.14%), Skylands Capital LLC (7.32%), Avenir Corp (6.87%), Neuberger Berman Group LLC (4.05%), Neuberger Berman Group LLC (4.05%) and Sargent Investment Group LLC (2.94%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTSO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.